Cardiol Therapeutics R&D spend
Cardiol Therapeutics Inc. · CRDL (TSX) · Oakville, ON · Pharmaceuticals
Latest R&D (CAD)
$14.0M
Period ended 2025-12-31
Revenue (CAD)
—
— of revenue
R&D by fiscal period
2025
$14.0M
2024
$14.0M
2023
$14.2M
2022
$19.0M
2021
$10.9M
2020
$10.6M
| Period end | R&D (CAD) | Revenue (CAD) | Native R&D | Form | Source |
|---|---|---|---|---|---|
| 2025-12-31 | $14,018,461 | — | $14,018,461 CAD | 40-F | SEC EDGAR |
| 2024-12-31 | $14,012,130 | — | $14,012,130 CAD | 40-F | SEC EDGAR |
| 2023-12-31 | $14,224,287 | — | $14,224,287 CAD | 40-F | SEC EDGAR |
| 2022-12-31 | $18,962,080 | — | $18,962,080 CAD | 20-F | SEC EDGAR |
| 2021-12-31 | $10,870,421 | $78,760 | $10,870,421 CAD | 20-F | SEC EDGAR |
| 2020-12-31 | $10,602,851 | — | $10,602,851 CAD | 20-F | SEC EDGAR |